top of page
Antibody System Anti-Alirocumab ELISA Kit

Antibody System Anti-Alirocumab ELISA Kit

This enzyme-linked immunosorbent assay (ELISA) kit is engineered for the precise quantitative determination of Anti-Alirocumab antibody concentrations in serum and plasma samples. Alirocumab is a fully human IgG1 monoclonal antibody that targets Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). By binding to circulating PCSK9, Alirocumab prevents it from degrading low-density lipoprotein receptors (LDLR) on the surface of hepatocytes, thereby increasing the number of available receptors to clear LDL cholesterol from the bloodstream. It serves as a frontline therapeutic strategy for managing primary hyperlipidemia and heterozygous familial hypercholesterolemia. This specialized ELISA platform is optimized for detecting and quantifying anti-drug antibodies (ADAs) generated against Alirocumab, acting as a critical analytical instrument for clinical investigators, cardiologists, and pharmacologists tracking long-term therapeutic immunogenicity, analyzing secondary drug resistance, and evaluating pharmacokinetic clearance variations.

 

DATASHEET

  • PRODUCT INFO

    Principle of the Assay

    This assay utilizes a high-performance, solid-phase quantitative sandwich enzyme immunoassay technique (bridging format) to measure specific anti-drug antibody levels:

    • Target Capture: Recombinant Alirocumab is uniformly pre-coated onto the solid-phase surface of a 96-well microplate.

    • Specific Binding: Calibrated standards or unknown biological samples are pipetted directly into the microwells. Endogenous Anti-Alirocumab antibodies present in the sample are bound and captured by the immobilized Alirocumab proteins.

    • Bridging Conjugation: Unbound matrix elements are removed via a rigorous wash cycle. A biotin-labeled Alirocumab tracer solution is introduced into the wells, binding to the open antigen-binding sites of the captured Anti-Alirocumab target, effectively forming an immune bridging complex.

    • Enzyme Complexing: Following another wash step to clear unbound tracer, Streptavidin conjugated to Horseradish Peroxidase (Streptavidin-HRP) is added to bind specifically to the biotinylated domains.

    • Signal Amplification and Readout: After a final wash to remove excess enzyme reagent, a colorimetric substrate solution is added to initiate enzymatic signal development. Because this is a bridging sandwich assembly, the resulting color intensity develops in direct proportion to the concentration of Anti-Alirocumab bound in the initial step. The reaction is terminated with a stop solution, and absorbance is quantified spectrophotometrically.

    Key Features and Performance Metrics

    • Sensitive Detection Capability: Exhibits an analytical sensitivity down to 101.12 ng/mL, facilitating the early tracking of low-level anti-drug antibody formations.

    • Extended Quantitative Range: Delivers a wide dynamic tracking range from 156.25 ng/mL to 10,000 ng/mL to accommodate diverse sample concentration tiers without immediate saturation.

    • Exceptional Assay Precision: Demonstrates excellent target reproducibility with a Coefficient of Variation (CV) of less than 15 percent, ensuring robust experimental uniformity.

    • Reliable Recovery Profile: Validated with a target recovery range between 80 percent and 120 percent, indicating low matrix interference in both human plasma and serum testing setups.

    Technical Specifications

    • Catalog No.: KAJ24001

    • Assay Configuration: Quantitative Bridging Sandwich Enzyme Immunoassay

    • Targeted Biomarker: Anti-Alirocumab (Anti-Drug Antibodies / ADA)

    • Validated Matrices: Plasma and Serum

    • Assay Range: 156.25 to 10,000 ng/mL

    • Analytical Sensitivity: 101.12 ng/mL

    • Detection Method: Colorimetric

    • Solid-Phase Target: Recombinant Alirocumab

    • Detection Enzyme Layer: Biotin-Alirocumab / Streptavidin-HRP Conjugate

    Alternative Names: Anti-REGN727, Anti-SAR-236553, Anti-SAR236553, Anti-SAR 236553, Anti-CAS 1245916-14-6.

    Applications and Workflow Summary

    This bridging sandwich ELISA platform is highly optimized for therapeutic drug immunogenicity monitoring and downstream pharmacokinetic profiling. Investigators should observe the following guidelines:

    • Dilution and Layout: Unknown serum or plasma matrices must be screened alongside the provided reference standards. Samples exhibiting target concentrations exceeding the maximum range of 10,000 ng/mL must be diluted empirically in standard assay matrix buffer prior to running the assay.

    • Analysis Requirements: To achieve absolute quantification accuracy, investigators must generate a standard curve simultaneously during every plate run, plotting standard absorbance profiles against log-transformed concentration values.

    Handling, Stability , and Storage

    • Kit Shipping: Distributed under secure, temperature-controlled conditions between 2 and 8 degrees Celsius to safeguard protein matrix and enzyme binding configurations.

    • Operational Shelf Life: Built with high-grade components to guarantee consistent, low-decay signal retention, demonstrating an activity loss rate of less than 20 percent prior to the expiration date when kept under appropriate storage conditions.

    • Storage Guidance: Keep the complete kit stored strictly at the recommended refrigeration temperature upon receipt. Ensure that unused microplate wells remain sealed within their original desiccant pouch to guard against moisture compromise.

Heading 6

Related Products

bottom of page